Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

CGON

Cg Oncology Inc

Jan 30 • 09:49AM ET

30.50

Dollar change +0.21
Percentage change 0.71	%

Healthcare • Biotechnology • USA • NASD

Peers: ONC BPMC EXEL PTCT PBYI FATE KURA MGNX GERN IMMP

| Held by: VTI VB IWM VBR XBI VXF IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	33.25%	Shs Outstand	67.54M	Perf Week	-0.80%
Market Cap	2.32B	Forward P/E	-	EPS next Y	-1.76	Insider Trans	-5.08%	Shs Float	45.14M	Perf Month	1.55%
Income	-78.29M	PEG	-	EPS next Q	-0.35	Inst Own	61.82%	Short Float	14.12%	Perf Quarter	-18.20%
Sales	0.68M	P/S	3415.20	EPS this Y	-13.72%	Inst Trans	20.16%	Short Ratio	9.06	Perf Half Y	-0.89%
Book/sh	7.95	P/B	3.84	EPS next Y	-37.25%	ROA	-	Short Interest	6.37M	Perf Year	-17.55%
Cash/sh	7.10	P/C	4.29	EPS next 5Y	-7.44%	ROE	-	52W Range	25.77 - 50.23	Perf YTD	6.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-14.58%	52W High	-39.27%	Beta	1.39
Dividend TTM	-	Quick Ratio	35.32	Sales past 5Y	-45.67%	Gross Margin	94.74%	52W Low	18.37%	ATR (14)	1.37
Dividend Ex-Date	-	Current Ratio	35.32	EPS Y/Y TTM	-	Oper. Margin	-13969.15%	RSI (14)	51.55	Volatility	4.18% 4.66%
Employees	61	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-11445.91%	Recom	1.00	Target Price	69.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-30.84%	Payout	-	Rel Volume	0.15	Prev Close	30.29
Sales Surprise	-61.95%	EPS Surprise	13.99%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	703.94K	Price	30.50
SMA20	2.14%	SMA50	-1.58%	SMA200	-10.17%	Trades		Volume	10,322	Change	0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
08:00AM	Loading…
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
08:23AM	Loading…
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
07:10PM	Loading…
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POST LEONARD E	Director	Jan 13 '25	Option Exercise	0.60	1,000	600	1,000	Jan 14 04:16 PM
POST LEONARD E	Director	Jan 13 '25	Sale	29.66	1,000	29,660	0	Jan 14 04:16 PM
Song Hong Fang	Director	Dec 16 '24	Sale	28.00	700,000	19,600,000	3,003,931	Dec 17 06:03 PM
POST LEONARD E	Director	Dec 16 '24	Option Exercise	0.60	1,000	600	1,000	Dec 17 05:00 PM
POST LEONARD E	Director	Dec 16 '24	Sale	28.84	1,000	28,840	0	Dec 17 05:00 PM
POST LEONARD E	Director	Dec 06 '24	Option Exercise	0.60	1,000	600	1,000	Dec 06 06:51 PM
POST LEONARD E	Director	Dec 06 '24	Sale	34.54	1,000	34,542	0	Dec 06 06:51 PM
LEONARD E POST	Director	Dec 06 '24	Proposed Sale	33.56	4,000	134,240		Dec 06 04:32 PM
Song Hong Fang	Director	Aug 29 '24	Sale	35.36	650,455	23,000,089	586,982	Aug 30 07:18 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 08:27 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 08:26 PM
Unique Diamond Investments Ltd	Director	Aug 29 '24	Proposed Sale	35.36	424,210	15,000,000		Aug 29 06:44 PM
Charming Jade Ltd	Director	Aug 29 '24	Proposed Sale	35.36	226,245	8,000,000		Aug 29 06:43 PM

Open in Screener

QURE

uniQure N.V

Jan 30 • 09:49AM ET

15.45

Dollar change +0.21
Percentage change 1.38	%

Healthcare • Biotechnology • Netherlands • NASD

Peers: SRPT BLUE CRSP BMRN NTLA SGMO RCKT EDIT ADVM BOLD

| Held by: VXF IBB PTH SCHA DWAS VHT PRFZ ITOT GNOM TMAT

Index	-	P/E	-	EPS (ttm)	-4.96	Insider Own	13.00%	Shs Outstand	48.74M	Perf Week	-2.40%
Market Cap	825.61M	Forward P/E	-	EPS next Y	-3.38	Insider Trans	-1.49%	Shs Float	46.49M	Perf Month	-11.71%
Income	-239.50M	PEG	-	EPS next Q	-0.65	Inst Own	74.08%	Short Float	7.56%	Perf Quarter	131.29%
Sales	28.59M	P/S	28.88	EPS this Y	36.90%	Inst Trans	32.55%	Short Ratio	1.58	Perf Half Y	102.49%
Book/sh	1.15	P/B	13.49	EPS next Y	17.31%	ROA	-31.57%	Short Interest	3.51M	Perf Year	157.93%
Cash/sh	8.14	P/C	1.90	EPS next 5Y	25.73%	ROE	-147.56%	52W Range	3.73 - 19.18	Perf YTD	-12.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.59%	ROI	-43.88%	52W High	-19.45%	Beta	0.38
Dividend TTM	-	Quick Ratio	6.51	Sales past 5Y	386.81%	Gross Margin	-36.48%	52W Low	314.21%	ATR (14)	1.05
Dividend Ex-Date	-	Current Ratio	6.51	EPS Y/Y TTM	-3.34%	Oper. Margin	-710.49%	RSI (14)	54.66	Volatility	5.91% 6.85%
Employees	480	Debt/Eq	8.85	Sales Y/Y TTM	-74.45%	Profit Margin	-837.80%	Recom	1.33	Target Price	37.10
Option/Short	Yes / Yes	LT Debt/Eq	8.78	EPS Q/Q	51.42%	Payout	-	Rel Volume	0.11	Prev Close	15.24
Sales Surprise	-66.65%	EPS Surprise	8.33%	Sales Q/Q	62.54%	Earnings	Nov 05 BMO	Avg Volume	2.23M	Price	15.45
SMA20	-0.94%	SMA50	20.07%	SMA200	103.41%	Trades		Volume	23,780	Change	1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78
Apr-01-21	Upgrade	Mizuho	Neutral → Buy	$52
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-24-20	Initiated	H.C. Wainwright	Buy	$80
Nov-11-20	Initiated	Berenberg	Buy
Nov-09-20	Initiated	Jefferies	Buy	$55
Nov-04-20	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$61
Aug-25-20	Initiated	Raymond James	Strong Buy	$75
Jul-31-20	Upgrade	Robert W. Baird	Neutral → Outperform	$57
Jun-25-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$56
Jun-25-20	Downgrade	Robert W. Baird	Outperform → Neutral	$58
Jun-25-20	Downgrade	Mizuho	Buy → Neutral	$90 → $61

Show Previous Ratings

Today 07:37AM	uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS (GlobeNewswire)
Jan-27-25 05:14PM	Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? (Insider Monkey)
Jan-13-25 04:17PM	Heres Why uniQure N.V. (QURE) Is Skyrocketing (Insider Monkey)
Jan-11-25 08:01PM	Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? (Insider Monkey)
Jan-08-25 07:05AM	uniQure Announces Pricing of its Public Offering (GlobeNewswire) -9.75%
04:49PM	Loading…
Jan-07-25 04:49PM	uniQure Announces Proposed Public Offering (GlobeNewswire)
Dec-17-24 07:20AM	uniQure price target raised to $32 from $12 at Stifel (TipRanks) -5.40%
Dec-15-24 04:31AM	Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? (Motley Fool)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily) +109.73%
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
07:07AM	UniQure shares soar on chance of speedy approval for Huntingtons therapy (BioPharma Dive)
07:05AM	uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease (GlobeNewswire)
Nov-29-24 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet (Zacks)
Nov-28-24 12:00PM	What Makes uniQure (QURE) a New Buy Stock (Zacks)
Nov-21-24 07:05AM	uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
09:55AM	Loading…
Nov-08-24 09:55AM	Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade (Zacks)
Nov-05-24 08:30AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.99%
07:26AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-29-24 10:01AM	UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-24 03:03PM	State Street Corp's Strategic Reduction in uniQure NV Holdings (GuruFocus.com)
Oct-15-24 07:05AM	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS (GlobeNewswire)
07:05AM	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS (GlobeNewswire)
Sep-23-24 07:05AM	uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease (GlobeNewswire) -5.78%
Aug-15-24 07:05AM	uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease (GlobeNewswire)
Aug-01-24 12:51PM	UniQure restructuring to claim 300 jobs (BioPharma Dive)
08:25AM	UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Jul-26-24 09:55AM	Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High? (Zacks)
07:05AM	Loading…
Jul-23-24 07:05AM	uniQure Announces Closing of Sale of Manufacturing Facility to Genezen (GlobeNewswire) +5.38%
Jul-12-24 07:12AM	uniQures shares soar on positive data for Huntingtons gene therapy (Clinical Trials Arena)
Jul-10-24 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet (Zacks) +51.72%
09:01AM	uniQure (QURE) Soars on New Huntington's Disease Study Data (Zacks)
05:49AM	uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains? (Zacks)
Jul-09-24 10:46AM	MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing (InvestorPlace) +76.46%
10:27AM	Why Is uniQure (QURE) Stock Up 51% Today? (InvestorPlace)
09:35AM	Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE) (Zacks)
08:05AM	UniQure stock surges on data for Huntingtons gene therapy (BioPharma Dive)
07:05AM	uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease (GlobeNewswire)
Jul-01-24 07:05AM	uniQure Announces Sale of Commercial Manufacturing Facility to Genezen (GlobeNewswire)
07:05AM	Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA (PR Newswire)
06:30AM	UniQure, with sale of plant, outsources Hemgenix manufacturing (BioPharma Dive)
Jun-03-24 07:05AM	uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntingtons Disease (GlobeNewswire) +7.68%
May-07-24 01:53PM	QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:24AM	UniQure: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-29-24 09:06AM	uniQure NV CEO Matthew Kapusta Sells 27,904 Shares (GuruFocus.com) -14.05%
Feb-28-24 08:35AM	uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization (GuruFocus.com)
08:20AM	UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:05AM	uniQure Announces 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey) +5.80%
Dec-19-23 07:15AM	Investors still arent sold on UniQures gene therapy for Huntingtons (BioPharma Dive) -16.79%
07:05AM	uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease (GlobeNewswire)
Dec-11-23 07:30PM	CSL Behring's HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B (PR Newswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-08-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:08AM	5 Best Falling Stocks To Buy Now (Insider Monkey)
Nov-29-23 07:05AM	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease (GlobeNewswire)
Nov-14-23 10:31PM	3 Micro-Cap Stocks That Could Be Moonshots (InvestorPlace) +10.33%
Nov-08-23 09:55AM	Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade (Zacks) -5.45%
Nov-07-23 08:25AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +12.68%
08:12AM	uniQure NV (QURE) Reports Q3 2023 Earnings: Net Loss Widens, Cash Position Strengthens (GuruFocus.com)
07:21AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-27-23 10:00AM	CSL and uniQure Win 2023 Prix Galien USA Award (PR Newswire)
Oct-26-23 02:14PM	Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B (PR Newswire)
10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-25-23 10:02AM	UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -5.65%
Oct-24-23 07:05AM	uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting (GlobeNewswire)
Oct-12-23 08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks) -8.68%
Oct-06-23 11:31AM	uniQure (QURE) Up on Restructuring Plans, Workforce Reduction (Zacks)
Oct-05-23 01:49PM	Why Shares of uniQure Are Up Thursday (Motley Fool) +11.61%
08:15AM	UPDATE 1-Gene therapy maker UniQure to cut about 20% of workforce (Reuters)
07:19AM	UniQure to lay off about 20% of workforce (Reuters)
07:05AM	uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs (GlobeNewswire)
Oct-02-23 07:05AM	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.90%
Sep-05-23 01:10PM	Why Shares of uniQure Are Dropping Tuesday (Motley Fool) -9.86%
07:05AM	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
Aug-26-23 03:51PM	3 Tantalizing Stocks to Buy for Under $10 (InvestorPlace)
Aug-06-23 08:05AM	Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be (Simply Wall St.)
Aug-01-23 09:05AM	UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:54AM	UniQure: Q2 Earnings Snapshot (AP Finance)
07:05AM	uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jul-27-23 08:35PM	Down More Than 40%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
06:02AM	Party Time: Brokers Just Made Major Increases To Their uniQure N.V. (NASDAQ:QURE) Earnings Forecasts (Simply Wall St.)
Jun-26-23 07:11AM	uniQure Announces Leadership Addition to Support Advancement of Clinical Programs (GlobeNewswire)
Jun-22-23 03:03PM	Why uniQure Stock Cratered This Week (Motley Fool)
10:17AM	uniQure (QURE) Falls on Mixed Huntington's Disease Study Results (Zacks)
Jun-21-23 08:00PM	QURE: Lowering target price to $13.00 (Argus Research) -40.23%
04:08PM	Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy (Investor's Business Daily)
11:46AM	Why uniQure Stock Is Crashing Today (Motley Fool)
07:05AM	uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntingtons Disease (GlobeNewswire)
Jun-20-23 07:05AM	uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy (GlobeNewswire)
07:00AM	CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B (PR Newswire)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Dec 10 '24	Option Exercise	14.71	100,000	1,471,000	697,915	Dec 12 04:54 PM
Kapusta Matthew C	CEO, Managing Director	Dec 10 '24	Sale	15.03	100,000	1,503,000	597,915	Dec 12 04:54 PM
Kapusta Matthew C	CEO, Managing Director	Dec 09 '24	Sale	7.63	3,418	26,079	597,915	Dec 10 05:03 PM
KLEMT CHRISTIAN	Chief Financial Officer	Dec 09 '24	Sale	7.55	1,796	13,560	166,713	Dec 10 04:54 PM
Matthew Kapusta	CEO	Dec 10 '24	Proposed Sale	15.03	100,000	1,503,491		Dec 10 04:33 PM
Abi-Saab Walid	Chief Medical Officer	Jun 26 '24	Sale	4.36	1,447	6,309	115,253	Jun 28 04:21 PM
CALOZ PIERRE	Chief Operating Officer	Jun 17 '24	Sale	4.81	2,936	14,122	115,707	Jun 20 08:53 AM
KLEMT CHRISTIAN	Chief Financial Officer	Jun 17 '24	Sale	4.80	1,611	7,733	164,837	Jun 20 08:49 AM
POST LEONARD E	Director	Jun 13 '24	Sale	5.14	2,222	11,421	15,999	Jun 18 06:11 PM
Potts Jeannette	Chief Legal Officer	Jun 13 '24	Sale	4.98	4,781	23,809	91,819	Jun 17 07:46 PM
Springhorn Jeremy P.	Director	Jun 13 '24	Sale	5.12	2,231	11,423	23,756	Jun 17 07:40 PM
Meek David D.	Director	Jun 13 '24	Sale	5.12	2,229	11,412	20,252	Jun 17 07:35 PM
Balachandran Madhavan	Director	Jun 13 '24	Sale	5.12	2,231	11,423	23,759	Jun 17 07:30 PM
Soteropoulos Paula	Director	Jun 13 '24	Sale	5.14	2,220	11,411	20,203	Jun 17 07:24 PM
Gut Robert	Director	Jun 13 '24	Sale	5.12	3,504	17,940	44,165	Jun 17 07:19 PM
Kaye Jack	Director	Jun 13 '24	Sale	5.16	2,218	11,445	6,501	Jun 17 07:14 PM
Jacques Rachelle Suzanne	Director	Jun 13 '24	Sale	5.14	2,221	11,416	14,408	Jun 17 06:42 PM
CALOZ PIERRE	Chief Operating Officer	Feb 26 '24	Sale	6.47	9,455	61,174	85,643	Feb 28 04:33 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 26 '24	Sale	6.38	15,906	101,480	116,948	Feb 28 04:21 PM
Kapusta Matthew C	CEO, Managing Director	Feb 26 '24	Sale	6.35	27,904	177,190	440,839	Feb 28 04:17 PM

CGON

Cg Oncology Inc

QURE

uniQure N.V

Upgrade your FINVIZ experience